Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19.
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100.
“If successful, we hope that treatments such as Aviptadil may change the chances of survival for these patients,” says Dr. Richard Lee, who is leading the trial at UCI. Carlos Puma for UCI Health”
Thompson Reuters TEL AVIV, March 29 (Reuters) – The U.S. Food & Drug Administration has authorised the start of a mid-stage trial by U.S.-Israeli NeuroRx and Relief Therapeutics for the use of Aviptadil to treat Acute Respiratory Distress in coronavirus patients. The companies said on Sunday they are recruiting study sites and pharmacies to begin […]
NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics’ (RLF).